Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Stakeholders
2. Research & Forecasting
2.1. Research Methodology
2.1.1. Research Instruments
2.1.1.1. Secondary Instrument
2.1.1.2. Primary Instrument
2.1.2. Research Approaches
2.1.2.1. Bottom-up Approach
2.1.2.2. Top-down Approach
2.1.3. Research Reliability & Validity
2.1.4. Research Assumptions
2.1.5. Vendor Inclusion Criteria
2.2. Forecasting Methodology
2.2.1. Methodology for Market Estimation & Forecasting
2.2.2. Significance and Importance of the Market Estimation & Forecasting
3. Executive Summary
4. Premium Insight
4.1. Market Connectivity
4.2. Market Data Feed
4.3. Market Vendor Ranking Analysis
4.4. Market Dynamics
4.4.1. Drivers
4.4.2. Restraints
4.4.3. Opportunities
4.4.4. Challenges
4.5. Porter's Five Forces Analysis
4.5.1. Threat of New Entrants
4.5.2. Threat of Substitutes
4.5.3. Bargaining Power of Customers
4.5.4. Bargaining Power of Suppliers
4.5.5. Industry Rivalry
5. Global Biosimilars Market, by Indication
5.1. Introduction
5.2. Autoimmune Diseases
5.3. Blood Disorders
5.4. Chronic Diseases
5.5. Growth Hormone Deficiency
5.6. Infectious Diseases
5.7. Oncology
6. Global Biosimilars Market, by Manufacturing
6.1. Introduction
6.2. Contract Manufacturing
6.3. In-House Manufacturing
7. Global Biosimilars Market, by Product
7.1. Introduction
7.2. Recombinant Glycosylated Proteins
7.2.1. Erythropoietin (EPO)
7.2.2. Follitropin
7.2.3. Monoclonal Antibodies (MABS)
7.2.3.1. Adalimumab
7.2.3.2. Infliximab
7.2.3.3. Rituximab
7.3. Recombinant Non-Glycosylated Proteins
7.3.1. Granulocyte Colony-Stimulating Factor (Filgrastim)
7.3.2. Insulin
7.3.3. Interferons
7.3.3.1. Interferon-Alpha
7.3.3.2. Interferon-Beta
7.3.4. Recombinant Human Growth Hormone (RHGH)
7.4. Recombinant Peptides
7.4.1. Calcitonin
7.4.2. Glucagon
8. Global Biosimilars Market, by Geography
8.1. Introduction
8.2. Americas Biosimilars Market
8.2.1. Americas Biosimilars Market, by Country
8.2.1.1. United States
8.2.1.2. Brazil
8.2.1.3. Canada
8.2.1.4. Mexico
8.2.1.5. Argentina
8.2.2. Americas Biosimilars Market, by Indication
8.2.3. Americas Biosimilars Market, by Manufacturing
8.2.4. Americas Biosimilars Market, by Product
8.3. Europe, Middle East & Africa Biosimilars Market
8.3.1. Europe, Middle East & Africa Biosimilars Market, by Country
8.3.1.1. United Kingdom
8.3.1.2. Germany
8.3.1.3. France
8.3.1.4. Saudi Arabia
8.3.1.5. United Arab Emirates
8.3.1.6. Italy
8.3.1.7. Russia
8.3.2. Europe, Middle East & Africa Biosimilars Market, by Indication
8.3.3. Europe, Middle East & Africa Biosimilars Market, by Manufacturing
8.3.4. Europe, Middle East & Africa Biosimilars Market, by Product
8.4. Asia-Pacific Biosimilars Market
8.4.1. Asia-Pacific Biosimilars Market, by Country
8.4.1.1. China
8.4.1.2. Japan
8.4.1.3. India
8.4.1.4. Australia
8.4.2. Asia-Pacific Biosimilars Market, by Indication
8.4.3. Asia-Pacific Biosimilars Market, by Manufacturing
8.4.4. Asia-Pacific Biosimilars Market, by Product
9. 360iResearch Competitive Strategic Window
9.1. Introduction
9.1.1. Leverage Zone
9.1.2. Vantage Zone
9.1.3. Speculative Zone
9.1.4. Bottleneck Zone
10. 360iResearch FPNV Positioning Matrix
10.1. Introduction
10.2. 360iResearch Scores
10.2.1. Forefront
10.2.2. Pathfinders
10.2.3. Niche
10.2.4. Vital
10.3. Business Strategy
10.4. Product Satisfaction
11. Competitive News Feed Analysis
12. Company Usability Profiles
12.1. 3SBio Inc.
12.2. APOGENIX GmbH
12.3. AbbVie Inc.
12.4. Akeso Biopharma, Inc.
12.5. Amgen Inc.
12.6. BeiGene Ltd
12.7. Biogen Inc.
12.8. Bristol-Myers Squibb Pharmaceuticals Limited
12.9. Genexine, Inc.,
12.10. InflaRx N.V.
12.11. Innovent Biologics, Inc.
12.12. Janssen Pharmaceuticals, Inc.
12.13. Merck Sharp & Dohme Corp.
12.14. Pfizer Inc.
12.15. Roche Holding AG
12.16. Shanghai Junshi Biosciences Co., Ltd.
13. Appendix
13.1. Top Reports
13.2. Author Details

LIST OF TABLES (35 TABLES)

TABLE 1. GLOBAL BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 2. GLOBAL BIOSIMILARS MARKET RANKING, BY VENDORS, 2017
TABLE 3. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD MILLION)
TABLE 4. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 5. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 6. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 7. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 8. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 9. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 10. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD MILLION)
TABLE 11. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2016 - 2024 (USD MILLION)
TABLE 18. AMERICAS BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 19. AMERICAS BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD MILLION)
TABLE 20. AMERICAS BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD MILLION)
TABLE 21. AMERICAS BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD MILLION)
TABLE 24. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD MILLION)
TABLE 25. EUROPE, MIDDLE EAST & AFRICA BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 26. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD MILLION)
TABLE 27. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY INDICATION, 2016 - 2024 (USD MILLION)
TABLE 28. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2016 - 2024 (USD MILLION)
TABLE 29. ASIA-PACIFIC BIOSIMILARS MARKET SIZE, BY PRODUCT, 2016 - 2024 (USD MILLION)
TABLE 30. 360IRESEARCH SCORES FOR FOREFRONT IN BIOSIMILARS MARKET
TABLE 31. 360IRESEARCH SCORES FOR PATHFINDERS IN BIOSIMILARS MARKET
TABLE 32. 360IRESEARCH SCORES FOR NICHE IN BIOSIMILARS MARKET
TABLE 33. 360IRESEARCH SCORES FOR VITAL IN BIOSIMILARS MARKET
TABLE 34. 360IRESEARCH FPNV POSITIONING MATRIX BUSINESS STRATEGY FOR BIOSIMILARS MARKET
TABLE 35. 360IRESEARCH FPNV POSITIONING MATRIX PRODUCT SATISFACTION FOR BIOSIMILARS MARKET

LIST OF FIGURES (31 TABLES)

FIGURE 1. GLOBAL BIOSIMILARS MARKET: YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL BIOSIMILARS MARKET: KEY RESEARCH METHODOLOGY
FIGURE 3. GLOBAL BIOSIMILARS MARKET: KEY RESEARCH INSTRUMENTS
FIGURE 4. GLOBAL BIOSIMILARS MARKET: KEY SECONDARY INSTRUMENT SOURCES
FIGURE 5. GLOBAL BIOSIMILARS MARKET: KEY POTENTIAL RESPONDENTS
FIGURE 6. GLOBAL BIOSIMILARS MARKET: KEY BREAKDOWN OF PRIMARY INSTRUMENT
FIGURE 7. GLOBAL BIOSIMILARS MARKET: KEY RESEARCH APPROACHES
FIGURE 8. GLOBAL BIOSIMILARS MARKET: KEY DATA TRIANGULATION
FIGURE 9. GLOBAL BIOSIMILARS MARKET: KEY RESEARCH ASSUMPTIONS
FIGURE 10. BIOSIMILARS MARKET: KEY MARKET CONNECTIVITY
FIGURE 11. GLOBAL BIOSIMILARS MARKET SIZE, 2016 - 2024 (USD MILLION)
FIGURE 12. GLOBAL BIOSIMILARS MARKET SIZE, BY INDICATION, 2017 VS 2024 (USD MILLION)
FIGURE 13. GLOBAL BIOSIMILARS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 14. GLOBAL BIOSIMILARS MARKET SIZE, BY BLOOD DISORDERS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 15. GLOBAL BIOSIMILARS MARKET SIZE, BY CHRONIC DISEASES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 16. GLOBAL BIOSIMILARS MARKET SIZE, BY GROWTH HORMONE DEFICIENCY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 17. GLOBAL BIOSIMILARS MARKET SIZE, BY INFECTIOUS DISEASES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 18. GLOBAL BIOSIMILARS MARKET SIZE, BY ONCOLOGY, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 19. GLOBAL BIOSIMILARS MARKET SIZE, BY MANUFACTURING, 2017 VS 2024 (USD MILLION)
FIGURE 20. GLOBAL BIOSIMILARS MARKET SIZE, BY CONTRACT MANUFACTURING, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 21. GLOBAL BIOSIMILARS MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 22. GLOBAL BIOSIMILARS MARKET SIZE, BY PRODUCT, 2017 VS 2024 (USD MILLION)
FIGURE 23. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 24. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 25. GLOBAL BIOSIMILARS MARKET SIZE, BY RECOMBINANT PEPTIDES, BY GEOGRAPHY, 2017 VS 2024 (USD MILLION)
FIGURE 26. GLOBAL BIOSIMILARS MARKET SIZE, BY GEOGRAPHY, 2017 (USD MILLION)
FIGURE 27. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET, BY INDICATION, 2024
FIGURE 28. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET, BY MANUFACTURING, 2024
FIGURE 29. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET, BY PRODUCT, 2024
FIGURE 30. 360IRESEARCH COMPETITIVE STRATEGIC WINDOW FOR GLOBAL BIOSIMILARS MARKET, BY GEOGRAPHY, 2024
FIGURE 31. 360IRESEARCH FPNV POSITIONING MATRIX FOR BIOSIMILARS MARKET